This is a case report of individualized therapy for DDX41-mutated AML. The investigators obtained consent from the patient presented in this report to publish information containing medical history, ...

Today is your first day working at the SCP Foundation, and it could very well be your last. That's because your assignment is to kill SCP 096, an anomaly also known as The Shy Guy, who is virtually ...

A research team at Oregon Health & Science University has discovered a promising new drug combination that may help people with acute myeloid leukemia (AML) overcome resistance to one of the most ...

A research team at Oregon Health & Science University has discovered a promising new drug combination that may help people with acute myeloid leukemia overcome resistance to one of the most common ...

Amphista Therapeutics has reported preclinical leukemia data on its protein degrader, positioning the Big Pharma-partnered biotech to target a 2026 start date for a phase 1 clinical trial. The data, ...

ORLANDO, Fla. — A new analysis of three decades of clinical trial data confirms that Black patients with acute myeloid leukemia (AML) have worse survival outcomes than White patients. However, ...

A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute myeloid leukemia (AML) is driving better survival and cure rates. Led by Mikkael ...

A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute myeloid leukemia (AML) is driving better survival and cure rates. Led by Mikkael ...

The FDA has approved ziftomenib (Komzifti, Kura Oncology) for adults with relapsed or refractory (R/R) acute myeloid leukemia (AML) harboring a nucleophosmin 1 (NPM1) mutation, which occurs in up to ...

Combining proteasome inhibitors with autophagy inhibitors disrupts acute myeloid leukemia (AML) cells' proteostasis, enhancing treatment efficacy and inducing programmed cell death. The novel therapy ...